Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcutis Biotherapeutics, Inc. $ARQT

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 86,485 shares of the company’s stock, valued at approximately $1,630,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of Arcutis Biotherapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in shares of Arcutis Biotherapeutics by 10.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock worth $124,000 after buying an additional 820 shares in the last quarter. Atlas Wealth LLC bought a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $138,000. Merit Financial Group LLC purchased a new position in Arcutis Biotherapeutics in the third quarter worth about $190,000. Quantbot Technologies LP purchased a new position in Arcutis Biotherapeutics in the second quarter worth about $145,000. Finally, Russell Investments Group Ltd. increased its stake in Arcutis Biotherapeutics by 4,562.5% during the second quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock worth $157,000 after acquiring an additional 10,950 shares during the last quarter.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock opened at $25.37 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.50 and a quick ratio of 3.28. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of -70.47 and a beta of 1.71. The firm has a 50-day moving average of $28.52 and a two-hundred day moving average of $22.16. Arcutis Biotherapeutics, Inc. has a 1 year low of $11.13 and a 1 year high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Tuesday, October 28th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.16. The business had revenue of $99.22 million for the quarter, compared to analyst estimates of $86.69 million. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. On average, research analysts forecast that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Sue-Jean Lin sold 25,272 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $30.78, for a total value of $777,872.16. Following the completion of the sale, the director directly owned 26,735 shares of the company’s stock, valued at $822,903.30. This represents a 48.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Burnett sold 2,490 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $28.98, for a total transaction of $72,160.20. Following the transaction, the insider owned 94,120 shares in the company, valued at approximately $2,727,597.60. The trade was a 2.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 253,912 shares of company stock worth $6,884,105. 9.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ARQT shares. Zacks Research lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. The Goldman Sachs Group raised their price target on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Arcutis Biotherapeutics in a research note on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Arcutis Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.20.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.